Biotechnology
Commented by Carsten Mainitz on September 30th, 2025 | 07:40 CEST
Antimony Resources, Rheinmetall, Novo Nordisk – Something is in the air!
Sufficient access to raw materials is crucial for any economy. The EU has compiled a list of 34 critical raw materials. How critical a raw material is classified depends on two parameters: "economic importance" and "supply risk." This list also includes a little-known but very important metalloid – antimony. The price of antimony skyrocketed at the end of 2024 in the wake of China's export ban. There are still exciting investment opportunities in this area.
ReadCommented by André Will-Laudien on September 30th, 2025 | 07:35 CEST
High-tech super boom! 1,000% no problem—here is more from D-Wave, NetraMark and Palantir!
Artificial intelligence (AI) is currently revolutionizing drug development by analyzing enormous amounts of data in a very short time and making clinical trials much more targeted. Modern AI systems make it possible to select drug candidates with precision and predict the potential success of a therapy with a high degree of accuracy. Companies like NetraMark are already using these technologies profitably. Players such as D-Wave and Palantir are also among the pioneers of the new AI-driven economy and have seen their share prices rise by over 1,000%. Expectations for further growth are virtually limitless. The advent of quantum computer technology also marks the beginning of a new chapter in ultra-fast data processing. For forward-looking investors, this opens up attractive entry opportunities in dynamically expanding future markets. Those who bet on the right players early on can benefit from this change to an above-average extent.
ReadCommented by André Will-Laudien on September 29th, 2025 | 07:20 CEST
Attention: Acquisitions! Biotechs like Evotec, PanGenomic Health, Pfizer, and BioNTech in focus
The biotech industry is in turmoil! With the expiration of blockbuster patents, there is a threat of sharp declines in revenue, which must be strategically compensated for. Driven by economic pressure and a growing focus on innovation and technology, the industry is increasingly turning to acquisitions of biotech companies with promising drug candidates, new technologies, and digital expertise. Not only are entire pipelines being acquired, but key players from the fastest-growing segments are also being targeted, particularly in the field of obesity therapies, where billions are being paid for drug candidates. Several examples illustrate this wave of transformation. Companies are restructuring, focusing their activities, and rapidly preparing for a phase of sustainable growth. The pace is picking up! Here are some promising investment ideas!
ReadCommented by Fabian Lorenz on September 29th, 2025 | 07:00 CEST
Takeover in the Ozempic market! BioNxt Solutions next? Novo Nordisk, Eli Lilly, and Pfizer are fighting!
The battle against obesity is considered one of the biggest growth markets in the global pharmaceutical sector. According to estimates, the market for obesity therapies could reach a volume of up to USD 150 billion by 2030. So far, Novo Nordisk and Eli Lilly have dominated the market. But almost every major corporation and innovative challenger wants a piece of the pie. The latest example: Pfizer is planning a billion-dollar takeover of US-based Metsera, a company competing with novel drugs against obesity. BioNxt Solutions is also a hot takeover candidate. The Company aims to revolutionize the market and attract new customers with an oral dosage form, and the first prototypes have already been developed. That makes it an attractive prospect for virtually every pharmaceutical company.
ReadCommented by Nico Popp on September 26th, 2025 | 07:30 CEST
AI is conquering increasingly more areas: SAP and Amazon are targeting small and mid-sized businesses, while NetraMark is winning over the biotech industry
Will AI become our new god? This question is currently being explored in depth by the German philosopher Markus Gabriel in a well-known German podcast. And although the question may cause unease for many, Gabriel's conclusions are ultimately anything but pessimistic. SAP and Amazon are also looking to the future with optimism: Together with OpenAI, they are now building an AI infrastructure in Germany. The goal: to enable public authorities and companies to use the latest AI tools in a legally compliant manner, without European data leaving the continent. The initiative demonstrates that AI will conquer many more areas in the coming years. One of these areas is medical research. The innovative company NetraMark is using its AI solution to deliver faster results and lower costs for future-focused projects, such as the fight against cancer.
ReadCommented by André Will-Laudien on September 26th, 2025 | 07:15 CEST
BioNxt Solutions – Biotech specialist with significant leverage in mega markets
Modern medicine faces an enormous challenge: More and more people are suffering from so-called diseases of affluence, such as obesity, diabetes, multiple sclerosis, and MASH, the dreaded fatty liver disease. At the same time, there is a growing need for innovative therapies and new dosage forms that make treatments more effective, simpler, and more patient-friendly. This is precisely where BioNxt Solutions comes in, a young biotech company that is addressing several billion-dollar markets with its patented thin-film technology. By enabling the oral administration of important active ingredients such as semaglutide and cladribine, BioNxt is not only opening up new therapeutic avenues but also significantly enhancing the effectiveness of existing drugs. At a time when pharmaceutical giants are investing billions in new solutions, BioNxt could become one of the most exciting future players in the industry.
ReadCommented by Nico Popp on September 23rd, 2025 | 07:00 CEST
What MASH could do for your portfolio: BioNxt, Roche, Novo Nordisk
Have you heard of MASH? The acronym stands for metabolic-associated steatohepatitis, which was previously simply called "fatty liver." Medications targeting this disease, which studies suggest affects around 6% of Americans, are being hailed as the next big trend in the biotech market. Overall, one in three overweight individuals is affected. Since many patients initially show no symptoms, MASH is considered particularly insidious. The growing discussion around the condition could turn many at-risk individuals into patients who take medication, which is excellent news for certain companies in the sector. For a small-cap stock, the hype surrounding MASH could even be transformative.
ReadCommented by Carsten Mainitz on September 22nd, 2025 | 07:55 CEST
AJN Resources, TUI, Evotec: Fresh capital and insider purchases!
Fresh capital, insider purchases, or significant changes in the shareholder base can be important signals regarding future share price performance. The leverage effect of fresh capital is particularly high for smaller companies. This is because projects can be launched with manageable amounts of capital, bringing important milestones closer. However, the stock market sometimes reacts late because small or micro-caps fly under the radar of the investor community. However, it is precisely this constellation that creates good opportunities for active and vigilant investors.
ReadCommented by Armin Schulz on September 22nd, 2025 | 07:40 CEST
BioNxt Solutions: Your chance to get in early on the next biotech blockbuster
Imagine a cancer treatment that doesn't affect the whole body, but instead acts only at the tumor site. Or a treatment for multiple sclerosis that no longer needs to be swallowed, but simply dissolves under the tongue. What sounds like a dream of the future is already being pursued with full force by the German-Canadian biotech company BioNxt Solutions. The Company is developing two innovative platform technologies that aim to solve some of the biggest challenges in modern medicine. For investors, this opens up extraordinary opportunities.
ReadCommented by Fabian Lorenz on September 18th, 2025 | 07:25 CEST
Adidas to take over Puma? Evotec with insider buying! 50% upside potential with AI stock NetraMark!
Adidas and Puma caught in merger fever? A US investor brings the spectacular idea into play. Is it a means of exerting pressure on Puma's management or a real possibility? What do analysts say? Meanwhile, Evotec is sending a signal of confidence with fresh insider purchases. However, the stock is still digesting the recent revenue forecast downgrade. Could there be fresh momentum next week? In contrast, NetraMark shares offer a 50% return. For this to happen, however, the AI-driven drug development specialist must reach the analysts' price target. Operationally, there is much to be said for this, and in comparative tests, the Company has outperformed ChatGPT and DeepSeek.
Read